GE HealthCare Technologies (GEHC) Financials

$62.67 +0.78 (+1.26%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$62.50 -0.17 (-0.27%)

As of 04:35 AM Eastern

Annual Income Statements for GE HealthCare Technologies

This table shows GE HealthCare Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	2,247	1,916	1,385	1,993	2,084
Consolidated Net Income / (Loss)	2,293	1,967	1,614	2,050	2,154
Net Income / (Loss) Continuing Operations	2,275	1,949	1,618	2,050	2,154
Total Pre-Tax Income	2,875	2,512	2,361	2,581	2,768
Total Operating Income	2,795	2,522	2,435	2,625	2,763
Total Gross Profit	7,174	7,179	7,922	8,205	8,248
Total Revenue	17,585	18,341	19,552	19,672	20,625
Operating Revenue	17,585	18,341	19,552	19,672	20,625
Total Cost of Revenue	10,411	11,162	11,630	11,467	12,378
Operating Cost of Revenue	10,411	11,162	11,630	11,467	12,378
Total Operating Expenses	4,379	4,657	5,487	5,580	5,485
Selling, General & Admin Expense	3,563	3,631	4,282	4,269	4,225
Research & Development Expense	816	1,026	1,205	1,311	1,260
Total Other Income / (Expense), net	80	-10	-74	-43	5.00
Interest Expense	40	77	542	504	440
Other Income / (Expense), net	120	67	468	461	445
Income Tax Expense	600	563	743	531	614
Net Income / (Loss) Discontinued Operations	18	18	-4.00	0.00	0.00
Preferred Stock Dividends Declared	0.00	0.00	183	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	46	51	46	57	70
Basic Earnings per Share	$4.95	$4.22	$3.05	$4.37	$4.56
Weighted Average Basic Shares Outstanding	454M	454M	455M	456M	456M
Diluted Earnings per Share	$4.95	$4.22	$3.03	$4.34	$4.55
Weighted Average Diluted Shares Outstanding	454M	454M	458M	459M	458M
Weighted Average Basic & Diluted Shares Outstanding	-	-	455.36M	457.30M	455.75M
Cash Dividends to Common per Share	-	-	$0.12	$0.13	$0.14

This table shows GE HealthCare Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	375	403	374	428	470	721	564	486	446	588	389
Consolidated Net Income / (Loss)	382	416	388	435	490	737	588	500	464	602	411
Net Income / (Loss) Continuing Operations	386	416	388	435	490	737	588	500	464	602	411
Total Pre-Tax Income	636	609	512	578	658	833	692	613	643	820	505
Total Operating Income	617	689	540	608	676	801	629	654	653	827	515
Total Gross Profit	1,935	2,156	1,902	2,002	2,026	2,275	2,012	1,985	1,990	2,261	1,977
Total Revenue	4,822	5,206	4,650	4,839	4,863	5,320	4,777	5,007	5,143	5,698	5,131
Operating Revenue	4,822	5,206	4,650	4,839	4,863	5,320	4,777	5,007	5,143	5,698	5,131
Total Cost of Revenue	2,887	3,050	2,749	2,837	2,838	3,043	2,765	3,023	3,154	3,436	3,154
Operating Cost of Revenue	2,887	3,050	2,749	2,837	2,838	3,043	2,765	3,023	3,154	3,436	3,154
Total Operating Expenses	1,318	1,467	1,362	1,394	1,350	1,474	1,384	1,331	1,337	1,433	1,462
Selling, General & Admin Expense	996	1,152	1,038	1,067	1,034	1,130	1,040	1,029	1,045	1,111	1,117
Research & Development Expense	322	315	324	327	316	344	344	302	292	322	345
Total Other Income / (Expense), net	19	-80	-28	-29	-19	33	63	-41	-10	-7.00	-9.00
Interest Expense	138	131	122	131	130	121	110	113	111	106	96
Other Income / (Expense), net	157	51	94	102	111	154	173	72	101	99	87
Income Tax Expense	250	193	124	143	168	96	104	113	179	218	94
Net Income / (Loss) Attributable to Noncontrolling Interest	7.00	13	14	7.00	19	17	24	14	18	14	22
Basic Earnings per Share	$0.82	$0.89	$0.82	$0.94	$1.03	$1.58	$1.23	$1.06	$0.98	$1.29	$0.85
Weighted Average Basic Shares Outstanding	455M	455M	456M	457M	457M	456M	457M	457M	456M	456M	456M
Diluted Earnings per Share	$0.82	$0.89	$0.81	$0.93	$1.02	$1.58	$1.23	$1.06	$0.98	$1.28	$0.85
Weighted Average Diluted Shares Outstanding	458M	458M	459M	459M	459M	459M	459M	458M	457M	458M	457M
Weighted Average Basic & Diluted Shares Outstanding	455.24M	455.36M	456.47M	456.66M	456.87M	457.30M	457.88M	456.56M	455.52M	455.75M	454.89M
Cash Dividends to Common per Share	$0.03	-	$0.03	$0.03	-	-	$0.04	-	-	-	$0.04

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-451	890	1,055	387	1,623
Net Cash From Operating Activities	1,607	2,113	2,101	1,951	1,987
Net Cash From Continuing Operating Activities	1,607	2,134	2,101	1,955	1,987
Net Income / (Loss) Continuing Operations	2,275	1,949	1,618	2,050	2,154
Consolidated Net Income / (Loss)	2,293	1,967	1,614	2,050	2,154
Net Income / (Loss) Discontinued Operations	18	18	-4.00	0.00	0.00
Depreciation Expense	225	228	248	268	287
Amortization Expense	400	405	362	312	291
Non-Cash Adjustments To Reconcile Net Income	45	-263	-306	-524	-387
Changes in Operating Assets and Liabilities, net	-1,338	-185	178	-151	-357
Net Cash From Discontinued Operating Activities	0.00	-21	0.00	-4.00	0.00
Net Cash From Investing Activities	-1,761	-398	-558	-914	-1,047
Net Cash From Continuing Investing Activities	-1,761	-398	-558	-914	-1,047
Purchase of Property, Plant & Equipment	-248	-310	-387	-401	-482
Acquisitions	-1,481	0.00	-147	-313	-378
Purchase of Investments	-	-59	-48	-40	-118
Sale of Property, Plant & Equipment	15	4.00	1.00	0.00	0.00
Other Investing Activities, net	-47	-33	23	-160	-69
Net Cash From Financing Activities	-263	-822	-478	-573	617
Net Cash From Continuing Financing Activities	-263	-822	-478	-572	618
Repayment of Debt	-23	-95	-904	-1,452	-1,848
Repurchase of Common Equity	0.00	0.00	-211	0.00	-200
Payment of Dividends	0.00	0.00	-41	-55	-64
Issuance of Debt	-2.00	8,207	1,994	995	2,735
Issuance of Common Equity	-	0.00	34	33	37
Other Financing Activities, net	-238	-8,934	-1,350	-93	-42
Effect of Exchange Rate Changes	-34	-3.00	-10	-77	66
Cash Interest Paid	21	0.00	570	550	522

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	475	86	59	-547	1,554	-679	-416	1,289	264	486	-2,227
Net Cash From Operating Activities	650	1,050	419	-119	738	913	250	94	593	1,050	290
Net Cash From Continuing Operating Activities	650	1,050	419	-121	744	913	250	95	592	1,050	288
Net Income / (Loss) Continuing Operations	386	416	388	435	489	738	588	500	464	602	411
Consolidated Net Income / (Loss)	382	416	388	435	489	738	588	500	464	602	411
Depreciation Expense	64	60	68	69	66	65	66	72	75	74	78
Amortization Expense	89	84	80	80	77	75	70	76	73	72	75
Non-Cash Adjustments To Reconcile Net Income	-64	-9.00	-105	-202	-91	-137	-230	-185	-14	42	-107
Changes in Operating Assets and Liabilities, net	175	499	-12	-503	203	171	-244	-368	-5.00	260	-169
Net Cash From Investing Activities	-120	-88	-188	-349	-137	-240	-407	-223	-148	-269	-2,500
Net Cash From Continuing Investing Activities	-120	-88	-188	-350	-137	-240	-407	-222	-149	-269	-2,501
Purchase of Property, Plant & Equipment	-80	-94	-145	-64	-90	-102	-152	-86	-110	-134	-178
Acquisitions	-	-	0.00	-259	-	-54	-269	-10	-	-99	-2,297
Purchase of Investments	-	-27	-19	-	-	-7.00	-20	-8.00	-54	-36	-13
Other Investing Activities, net	-19	33	-24	-27	-14	-77	34	-118	15	-	-13
Net Cash From Financing Activities	-24	-900	-153	-57	914	-1,277	-286	1,361	-165	-293	21
Net Cash From Continuing Financing Activities	-24	-900	-153	-57	914	-1,276	-286	1,360	-165	-291	21
Repayment of Debt	-33	-871	-146	-42	-7.00	-1,262	-263	-13	-45	-1,527	-1,005
Repurchase of Common Equity	-	-	-	-	-	-	0.00	-	-100	-	-100
Payment of Dividends	-14	-13	-14	-14	-13	-14	-16	-16	-16	-16	-16
Issuance of Debt	23	-17	2.00	-1.00	993	1.00	1.00	1,493	-	1,241	1,151
Issuance of Common Equity	-	3.00	16	-	-	2.00	20	1.00	4.00	12	10
Other Financing Activities, net	-31	-2.00	-11	-	-90	-3.00	-28	-5.00	-8.00	-1.00	-19
Effect of Exchange Rate Changes	-31	24	-19	-22	39	-75	27	57	-16	-2.00	-37
Cash Interest Paid	68	252	55	219	65	211	78	182	67	195	87

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	27,539	32,454	33,089	36,906
Total Current Assets	8,318	9,410	9,901	12,501
Cash & Equivalents	1,445	2,504	2,889	4,512
Accounts Receivable	3,312	3,557	3,566	3,955
Inventories, net	2,155	1,960	1,939	2,234
Other Current Assets	1,406	1,389	1,506	1,799
Plant, Property, & Equipment, net	2,314	2,500	2,550	3,092
Total Noncurrent Assets	16,907	20,544	20,638	21,315
Goodwill	12,813	12,936	13,136	13,489
Intangible Assets	1,520	1,253	1,078	1,130
Noncurrent Deferred & Refundable Income Taxes	1,550	4,474	4,474	4,491
Other Noncurrent Operating Assets	1,024	1,881	1,950	2,205
Total Liabilities & Shareholders' Equity	27,539	32,454	33,089	36,906
Total Liabilities	17,947	25,144	24,437	26,307
Total Current Liabilities	7,191	8,981	9,553	9,105
Short-Term Debt	15	1,006	1,502	508
Accounts Payable	2,944	2,947	3,035	3,250
Current Employee Benefit Liabilities	-	1,518	1,521	1,666
Other Current Liabilities	4,232	3,510	3,495	3,682
Total Noncurrent Liabilities	10,756	16,163	14,884	17,202
Long-Term Debt	8,234	8,436	7,449	9,495
Noncurrent Deferred & Payable Income Tax Liabilities	370	68	56	193
Noncurrent Employee Benefit Liabilities	549	5,782	5,583	5,453
Other Noncurrent Operating Liabilities	1,603	1,877	1,796	2,061
Commitments & Contingencies	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	230	165	188	209
Total Equity & Noncontrolling Interests	9,362	7,145	8,464	10,390
Total Preferred & Common Equity	9,357	7,133	8,446	10,379
Total Common Equity	9,357	7,133	8,446	10,380
Common Stock	0.00	6,498	6,588	6,712
Retained Earnings	0.00	1,326	3,262	5,281
Treasury Stock	-	0.00	-25	-225
Accumulated Other Comprehensive Income / (Loss)	-1,878	-691	-1,379	-1,388
Noncontrolling Interest	5.00	12	18	11

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	32,311	32,382	32,454	32,208	31,852	33,855	33,089	33,586	35,500	36,127	37,125
Total Current Assets	9,240	9,468	9,410	9,373	8,806	10,638	9,901	9,735	11,308	11,893	10,426
Cash & Equivalents	1,939	2,418	2,504	2,563	2,015	3,568	2,889	2,473	3,763	4,027	2,285
Accounts Receivable	3,397	3,400	3,557	3,344	3,354	3,424	3,569	3,572	3,562	3,734	3,786
Inventories, net	2,264	2,128	1,960	1,989	2,023	2,124	1,939	2,158	2,283	2,304	2,353
Other Current Assets	1,640	1,522	1,389	1,478	1,414	1,522	1,503	1,532	1,700	1,827	2,001
Plant, Property, & Equipment, net	2,357	2,355	2,500	2,445	2,458	2,539	2,550	2,851	2,962	3,010	3,095
Total Noncurrent Assets	20,802	20,559	20,544	20,392	20,589	20,677	20,638	20,999	21,230	21,224	23,605
Goodwill	12,929	12,914	12,936	12,927	13,116	13,138	13,136	13,373	13,417	13,441	15,060
Intangible Assets	1,423	1,332	1,253	1,174	1,195	1,132	1,078	1,238	1,220	1,163	1,908
Noncurrent Deferred & Refundable Income Taxes	4,349	4,277	4,474	4,413	4,365	4,309	4,474	4,462	4,517	4,468	4,383
Other Noncurrent Operating Assets	2,101	2,036	1,881	1,878	1,913	2,098	1,950	1,926	2,076	2,152	2,254
Total Liabilities & Shareholders' Equity	32,311	32,382	32,454	32,208	31,852	33,855	33,089	33,586	35,500	36,127	37,125
Total Liabilities	24,988	25,079	25,144	24,609	23,858	25,343	24,437	24,168	25,548	25,907	26,227
Total Current Liabilities	7,581	7,565	8,981	8,859	8,318	8,670	9,553	9,969	9,748	10,073	8,529
Short-Term Debt	5.00	7.00	1,006	1,008	1,007	1,007	1,502	2,002	2,005	2,005	7.00
Accounts Payable	2,835	2,774	2,947	2,931	2,824	2,911	3,022	3,152	2,975	2,987	3,410
Current Employee Benefit Liabilities	-	-	1,518	-	1,235	1,422	1,521	1,343	1,364	1,542	1,418
Other Current Liabilities	4,741	4,784	3,510	4,920	3,251	3,331	3,508	3,472	3,405	3,538	3,695
Total Noncurrent Liabilities	17,539	17,514	16,163	15,751	15,539	16,673	14,884	14,199	15,799	15,835	17,698
Long-Term Debt	10,233	10,253	8,436	8,247	8,233	9,306	7,449	6,757	8,270	8,277	10,127
Noncurrent Deferred & Payable Income Tax Liabilities	81	62	68	68	55	59	56	159	173	171	256
Noncurrent Employee Benefit Liabilities	5,167	5,373	5,782	5,625	5,455	5,388	5,583	5,443	5,351	5,287	5,300
Other Noncurrent Operating Liabilities	2,058	1,826	1,877	1,811	1,796	1,920	1,796	1,840	2,005	2,100	2,015
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	209	161	165	177	177	177	188	211	220	204	218
Total Equity & Noncontrolling Interests	7,114	7,142	7,145	7,423	7,817	8,335	8,464	9,207	9,733	10,016	10,680
Total Preferred & Common Equity	7,102	7,131	7,133	7,408	7,801	8,317	8,446	9,187	9,712	9,993	10,668
Total Common Equity	7,102	7,131	7,133	7,409	7,801	8,318	8,446	9,188	9,713	9,994	10,669
Common Stock	6,456	6,474	6,498	6,509	6,545	6,556	6,588	6,602	6,633	6,666	6,738
Retained Earnings	576	937	1,326	1,687	2,101	2,558	3,262	3,810	4,295	4,709	5,654
Treasury Stock	-	-	0.00	-	-	-25	-25	-25	-125	-225	-325
Accumulated Other Comprehensive Income / (Loss)	70	-280	-691	-787	-845	-771	-1,379	-1,199	-1,090	-1,156	-1,398
Noncontrolling Interest	12	11	12	14	16	18	18	20	21	23	12

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	4.30%	6.60%	0.61%	4.84%
EBITDA Growth	0.00%	-8.98%	9.03%	4.36%	3.27%
EBIT Growth	0.00%	-11.18%	12.13%	6.30%	3.95%
NOPAT Growth	0.00%	-11.53%	-14.72%	24.94%	3.13%
Net Income Growth	0.00%	-14.22%	-17.95%	27.01%	5.07%
EPS Growth	0.00%	-14.75%	-28.20%	43.23%	4.84%
Operating Cash Flow Growth	0.00%	31.49%	-0.57%	-7.14%	1.85%
Free Cash Flow Firm Growth	0.00%	0.00%	126.43%	-57.56%	-52.28%
Invested Capital Growth	0.00%	0.00%	-13.10%	3.26%	9.36%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.58%	1.87%
EBITDA Q/Q Growth	0.00%	0.00%	463.88%	6.11%	-0.60%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	7.49%	-0.90%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	13.10%	-4.56%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	18.57%	-5.90%
EPS Q/Q Growth	0.00%	0.00%	0.00%	18.90%	-6.19%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.38%	-6.56%	7.41%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-6.55%	-25.22%
Invested Capital Q/Q Growth	0.00%	0.00%	-5.92%	-3.55%	-2.33%
Profitability Metrics	-	-	-	-	-
Gross Margin	40.80%	39.14%	40.52%	41.71%	39.99%
EBITDA Margin	20.13%	17.57%	17.97%	18.64%	18.36%
Operating Margin	15.89%	13.75%	12.45%	13.34%	13.40%
EBIT Margin	16.58%	14.12%	14.85%	15.69%	15.55%
Profit (Net Income) Margin	13.04%	10.72%	8.25%	10.42%	10.44%
Tax Burden Percent	79.76%	78.30%	68.36%	79.43%	77.82%
Interest Burden Percent	98.63%	97.03%	81.33%	83.64%	86.28%
Effective Tax Rate	20.87%	22.41%	31.47%	20.57%	22.18%
Return on Invested Capital (ROIC)	0.00%	23.87%	10.89%	14.40%	13.96%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	24.17%	10.09%	13.86%	14.03%
Return on Net Nonoperating Assets (RNNOA)	0.00%	17.14%	8.21%	11.29%	8.42%
Return on Equity (ROE)	0.00%	41.01%	19.10%	25.69%	22.38%
Cash Return on Invested Capital (CROIC)	0.00%	-176.13%	24.91%	11.19%	5.02%
Operating Return on Assets (OROA)	0.00%	9.40%	9.68%	9.42%	9.17%
Return on Assets (ROA)	0.00%	7.14%	5.38%	6.26%	6.15%
Return on Common Equity (ROCE)	0.00%	40.01%	18.63%	25.07%	21.88%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.02%	22.63%	24.27%	0.00%
Net Operating Profit after Tax (NOPAT)	2,212	1,957	1,669	2,085	2,150
NOPAT Margin	12.58%	10.67%	8.53%	10.60%	10.42%
Net Nonoperating Expense Percent (NNEP)	0.00%	-0.30%	0.80%	0.54%	-0.07%
Return On Investment Capital (ROIC_SIMPLE)	-	11.11%	10.06%	11.97%	10.54%
Cost of Revenue to Revenue	59.20%	60.86%	59.48%	58.29%	60.01%
SG&A Expenses to Revenue	20.26%	19.80%	21.90%	21.70%	20.48%
R&D to Revenue	4.64%	5.59%	6.16%	6.66%	6.11%
Operating Expenses to Revenue	24.90%	25.39%	28.06%	28.37%	26.59%
Earnings before Interest and Taxes (EBIT)	2,915	2,589	2,903	3,086	3,208
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,540	3,222	3,513	3,666	3,786
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	4.91	4.20	3.59
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	1.79	1.80	1.80
Price to Earnings (P/E)	0.00	0.00	25.29	17.80	17.86
Dividend Yield	0.00%	0.00%	0.12%	0.15%	0.17%
Earnings Yield	0.00%	0.00%	3.95%	5.62%	5.60%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	2.96	2.84	2.67
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	2.16	2.12	2.08
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	12.00	11.39	11.34
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	14.52	13.53	13.38
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	25.26	20.02	19.97
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	20.06	21.39	21.60
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	11.04	25.77	55.53
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.86	1.29	1.03	0.94
Long-Term Debt to Equity	0.00	0.86	1.15	0.86	0.90
Financial Leverage	0.00	0.71	0.81	0.81	0.60
Leverage Ratio	0.00	2.87	3.55	4.11	3.64
Compound Leverage Factor	0.00	2.79	2.89	3.43	3.14
Debt to Total Capital	0.00%	46.24%	56.36%	50.85%	48.55%
Short-Term Debt to Total Capital	0.00%	0.08%	6.01%	8.53%	2.47%
Long-Term Debt to Total Capital	0.00%	46.15%	50.36%	42.32%	46.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	1.32%	1.06%	1.17%	1.07%
Common Equity to Total Capital	0.00%	52.45%	42.58%	47.98%	50.38%
Debt to EBITDA	0.00	2.56	2.69	2.44	2.64
Net Debt to EBITDA	0.00	2.11	1.98	1.65	1.45
Long-Term Debt to EBITDA	0.00	2.56	2.40	2.03	2.51
Debt to NOPAT	0.00	4.22	5.66	4.29	4.65
Net Debt to NOPAT	0.00	3.48	4.16	2.91	2.55
Long-Term Debt to NOPAT	0.00	4.21	5.06	3.57	4.42
Altman Z-Score	0.00	0.00	1.81	1.92	2.01
Noncontrolling Interest Sharing Ratio	0.00%	2.45%	2.44%	2.40%	2.21%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	1.16	1.05	1.04	1.37
Quick Ratio	0.00	0.66	0.67	0.68	0.93
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-14,439	3,817	1,620	773
Operating Cash Flow to CapEx	689.70%	690.52%	544.30%	486.53%	412.24%
Free Cash Flow to Firm to Interest Expense	0.00	-187.52	7.04	3.21	1.76
Operating Cash Flow to Interest Expense	40.18	27.44	3.88	3.87	4.52
Operating Cash Flow Less CapEx to Interest Expense	34.35	23.47	3.16	3.08	3.42
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.67	0.65	0.60	0.59
Accounts Receivable Turnover	0.00	5.54	5.69	5.52	5.48
Inventory Turnover	0.00	5.18	5.65	5.88	5.93
Fixed Asset Turnover	0.00	7.93	8.12	7.79	7.31
Accounts Payable Turnover	0.00	3.79	3.95	3.84	3.94
Days Sales Outstanding (DSO)	0.00	65.91	64.12	66.11	66.55
Days Inventory Outstanding (DIO)	0.00	70.47	64.57	62.05	61.53
Days Payable Outstanding (DPO)	0.00	96.27	92.44	95.00	92.67
Cash Conversion Cycle (CCC)	0.00	40.11	36.25	33.16	35.41
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	16,396	14,248	14,713	16,090
Invested Capital Turnover	0.00	2.24	1.28	1.36	1.34
Increase / (Decrease) in Invested Capital	0.00	16,396	-2,148	465	1,377
Enterprise Value (EV)	0.00	0.00	42,147	41,741	42,927
Market Capitalization	0.00	0.00	35,032	35,473	37,216
Book Value per Share	$0.00	$20.61	$15.67	$18.49	$22.79
Tangible Book Value per Share	$0.00	($10.96)	($15.50)	($12.63)	($9.31)
Total Capital	0.00	17,841	16,752	17,603	20,602
Total Debt	0.00	8,249	9,442	8,951	10,003
Total Long-Term Debt	0.00	8,234	8,436	7,449	9,495
Net Debt	0.00	6,804	6,938	6,062	5,491
Capital Expenditures (CapEx)	233	306	386	401	482
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-303	-1,069	-1,039	-608
Debt-free Net Working Capital (DFNWC)	0.00	1,142	1,435	1,850	3,904
Net Working Capital (NWC)	0.00	1,127	429	348	3,396
Net Nonoperating Expense (NNE)	-81	-10	55	35	-3.89
Net Nonoperating Obligations (NNO)	0.00	6,804	6,938	6,061	5,491
Total Depreciation and Amortization (D&A)	625	633	610	580	578
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-1.65%	-5.47%	-5.28%	-2.95%
Debt-free Net Working Capital to Revenue	0.00%	6.23%	7.34%	9.40%	18.93%
Net Working Capital to Revenue	0.00%	6.14%	2.19%	1.77%	16.47%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$3.05	$4.37	$4.56
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	455M	456M	456M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$3.03	$4.34	$4.55
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	458M	459M	458M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	455.36M	457.30M	455.75M
Normalized Net Operating Profit after Tax (NOPAT)	2,212	1,957	1,669	2,085	2,150
Normalized NOPAT Margin	12.58%	10.67%	8.53%	10.60%	10.42%
Pre Tax Income Margin	16.35%	13.70%	12.08%	13.12%	13.42%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	72.88	33.62	5.36	6.12	7.29
NOPAT to Interest Expense	55.29	25.41	3.08	4.14	4.89
EBIT Less CapEx to Interest Expense	67.05	29.65	4.64	5.33	6.20
NOPAT Less CapEx to Interest Expense	49.47	21.44	2.37	3.34	3.79
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	2.54%	2.68%	2.97%
Augmented Payout Ratio	0.00%	0.00%	15.61%	2.68%	12.26%

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	455,749,767.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	455,749,767.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.85
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.38%	0.00%	-1.21%	0.46%	0.85%	2.19%	2.73%	3.47%	5.76%	7.11%	7.41%
EBITDA Growth	48.56%	463.06%	-6.79%	-0.46%	0.32%	23.87%	19.95%	1.75%	-3.01%	-2.10%	-19.51%
EBIT Growth	24.04%	0.00%	-7.04%	0.42%	1.68%	29.05%	26.50%	2.25%	-4.19%	-3.04%	-24.94%
NOPAT Growth	-21.91%	0.00%	4.36%	5.68%	34.43%	50.58%	30.61%	16.58%	-6.39%	-14.33%	-21.58%
Net Income Growth	-22.52%	0.00%	1.31%	0.46%	28.27%	77.16%	51.55%	14.94%	-5.31%	-18.32%	-30.10%
EPS Growth	-23.36%	0.00%	97.56%	2.20%	24.39%	77.53%	51.85%	13.98%	-3.92%	-18.99%	-30.89%
Operating Cash Flow Growth	0.00%	0.77%	-10.47%	-77.61%	13.54%	-13.05%	-40.33%	178.99%	-19.65%	15.01%	16.00%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	102.66%	-90.69%	93.69%	95.20%	-290.08%	-415.92%	-199.69%
Invested Capital Growth	0.00%	-13.10%	0.00%	0.00%	0.73%	3.26%	9.87%	8.16%	7.99%	9.36%	19.38%
Revenue Q/Q Growth	0.10%	7.96%	0.00%	4.06%	0.50%	9.40%	-10.21%	4.81%	2.72%	10.79%	-9.95%
EBITDA Q/Q Growth	7.42%	-4.64%	443.06%	9.85%	8.27%	17.74%	-14.34%	-6.82%	3.20%	18.85%	-29.57%
EBIT Q/Q Growth	9.48%	-4.39%	0.00%	11.99%	10.85%	21.35%	-16.02%	-9.48%	3.86%	22.81%	-34.99%
NOPAT Q/Q Growth	-13.52%	25.68%	0.00%	11.82%	10.02%	40.78%	-24.58%	-0.19%	-11.67%	28.85%	-30.97%
Net Income Q/Q Growth	-11.78%	8.90%	0.00%	12.11%	12.64%	50.41%	-20.22%	-14.97%	-7.20%	29.74%	-31.73%
EPS Q/Q Growth	-9.89%	8.54%	0.00%	14.81%	9.68%	54.90%	-22.15%	-13.82%	-7.55%	30.61%	-33.59%
Operating Cash Flow Q/Q Growth	1,070.15%	61.54%	-60.10%	-128.40%	720.17%	23.71%	-72.62%	-62.40%	530.85%	77.07%	-72.38%
Free Cash Flow Firm Q/Q Growth	0.00%	117.73%	-746.36%	-6.34%	102.66%	-38.06%	-459.28%	19.07%	-5.54%	-2.95%	-240.82%
Invested Capital Q/Q Growth	0.00%	-5.92%	0.32%	6.50%	0.22%	-3.55%	6.73%	4.85%	0.06%	-2.33%	16.51%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	40.13%	41.41%	40.90%	41.37%	41.66%	42.76%	42.12%	39.64%	38.69%	39.68%	38.53%
EBITDA Margin	19.22%	16.98%	16.82%	17.75%	19.12%	20.58%	19.64%	17.46%	17.54%	18.81%	14.71%
Operating Margin	12.80%	13.23%	11.61%	12.56%	13.90%	15.06%	13.17%	13.06%	12.70%	14.51%	10.04%
EBIT Margin	16.05%	14.21%	13.63%	14.67%	16.18%	17.95%	16.79%	14.50%	14.66%	16.25%	11.73%
Profit (Net Income) Margin	7.92%	7.99%	8.34%	8.99%	10.08%	13.85%	12.31%	9.99%	9.02%	10.57%	8.01%
Tax Burden Percent	60.06%	68.31%	75.78%	75.26%	74.47%	88.48%	84.97%	81.57%	72.16%	73.41%	81.39%
Interest Burden Percent	82.17%	82.30%	80.76%	81.41%	83.61%	87.23%	86.28%	84.44%	85.28%	88.55%	83.89%
Effective Tax Rate	39.31%	31.69%	24.22%	24.74%	25.53%	11.52%	15.03%	18.43%	27.84%	26.59%	18.61%
Return on Invested Capital (ROIC)	0.00%	11.54%	24.01%	24.25%	13.32%	18.10%	14.77%	13.43%	11.69%	14.27%	9.95%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	10.74%	23.37%	23.62%	13.14%	18.53%	15.59%	12.94%	11.58%	14.18%	9.83%
Return on Net Nonoperating Assets (RNNOA)	0.00%	8.73%	20.58%	21.36%	12.11%	15.09%	11.89%	9.91%	8.04%	8.51%	6.84%
Return on Equity (ROE)	0.00%	20.27%	44.59%	45.61%	25.43%	33.19%	26.66%	23.33%	19.73%	22.78%	16.79%
Cash Return on Invested Capital (CROIC)	0.00%	24.91%	-176.42%	-177.56%	11.40%	11.19%	5.35%	6.58%	6.52%	5.02%	-5.89%
Operating Return on Assets (OROA)	0.00%	9.27%	16.51%	17.98%	9.56%	10.78%	10.10%	8.60%	8.48%	9.58%	6.96%
Return on Assets (ROA)	0.00%	5.21%	10.10%	11.02%	5.95%	8.32%	7.41%	5.92%	5.22%	6.23%	4.75%
Return on Common Equity (ROCE)	0.00%	19.78%	43.47%	44.51%	24.85%	32.39%	26.00%	22.77%	19.29%	22.28%	16.41%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	21.85%	20.78%	20.79%	0.00%	24.49%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	374	471	409	458	503	709	534	533	471	607	419
NOPAT Margin	7.77%	9.04%	8.80%	9.46%	10.35%	13.32%	11.19%	10.65%	9.16%	10.66%	8.17%
Net Nonoperating Expense Percent (NNEP)	-0.19%	0.80%	0.63%	0.62%	0.18%	-0.44%	-0.83%	0.49%	0.11%	0.09%	0.12%
Return On Investment Capital (ROIC_SIMPLE)	-	2.84%	-	-	-	4.07%	2.97%	2.67%	2.32%	2.98%	2.01%
Cost of Revenue to Revenue	59.87%	58.59%	59.12%	58.63%	58.36%	57.20%	57.88%	60.38%	61.33%	60.30%	61.47%
SG&A Expenses to Revenue	20.66%	22.13%	22.32%	22.05%	21.26%	21.24%	21.77%	20.55%	20.32%	19.50%	21.77%
R&D to Revenue	6.68%	6.05%	6.97%	6.76%	6.50%	6.47%	7.20%	6.03%	5.68%	5.65%	6.72%
Operating Expenses to Revenue	27.33%	28.18%	29.29%	28.81%	27.76%	27.71%	28.97%	26.58%	26.00%	25.15%	28.49%
Earnings before Interest and Taxes (EBIT)	774	740	634	710	787	955	802	726	754	926	602
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	927	884	782	859	930	1,095	938	874	902	1,072	755
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.32	4.91	5.57	4.53	5.12	4.20	3.99	3.46	3.41	3.59	3.03
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	1.79	2.12	1.81	2.18	1.80	1.85	1.68	1.68	1.80	1.54
Price to Earnings (P/E)	0.00	25.29	26.28	22.38	25.43	17.80	16.77	15.00	15.37	17.86	16.92
Dividend Yield	0.09%	0.12%	0.13%	0.19%	0.13%	0.15%	0.16%	0.18%	0.18%	0.17%	0.20%
Earnings Yield	0.00%	3.95%	3.81%	4.47%	3.93%	5.62%	5.96%	6.67%	6.51%	5.60%	5.91%
Enterprise Value to Invested Capital (EV/IC)	2.56	2.96	3.37	2.81	3.25	2.84	2.75	2.45	2.46	2.67	2.15
Enterprise Value to Revenue (EV/Rev)	0.00	2.16	2.47	2.19	2.53	2.12	2.18	2.02	2.00	2.08	1.92
Enterprise Value to EBITDA (EV/EBITDA)	62.34	12.00	13.93	12.39	14.33	11.39	11.29	10.52	10.65	11.34	11.21
Enterprise Value to EBIT (EV/EBIT)	0.00	14.52	16.86	14.97	17.25	13.53	13.26	12.34	12.53	13.38	13.42
Enterprise Value to NOPAT (EV/NOPAT)	0.00	25.26	28.57	25.05	26.87	20.02	19.50	17.66	18.00	19.97	19.90
Enterprise Value to Operating Cash Flow (EV/OCF)	18.56	20.06	23.46	21.39	23.72	21.39	24.21	20.23	21.92	21.60	19.92
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	11.04	0.00	0.00	28.57	25.77	53.80	38.69	39.23	55.53	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.40	1.29	1.22	1.16	1.21	1.03	0.93	1.03	1.01	0.94	0.93
Long-Term Debt to Equity	1.40	1.15	1.09	1.03	1.09	0.86	0.72	0.83	0.81	0.90	0.93
Financial Leverage	1.07	0.81	0.88	0.90	0.92	0.81	0.76	0.77	0.69	0.60	0.70
Leverage Ratio	4.43	3.55	4.24	3.98	4.19	4.11	3.87	3.75	3.74	3.64	3.48
Compound Leverage Factor	3.64	2.92	3.42	3.24	3.50	3.58	3.34	3.17	3.19	3.22	2.92
Debt to Total Capital	58.42%	56.36%	54.91%	53.61%	54.78%	50.85%	48.19%	50.80%	50.15%	48.55%	48.18%
Short-Term Debt to Total Capital	0.04%	6.01%	5.98%	5.84%	5.35%	8.53%	11.01%	9.91%	9.78%	2.47%	0.03%
Long-Term Debt to Total Capital	58.38%	50.36%	48.93%	47.77%	49.43%	42.32%	37.17%	40.88%	40.37%	46.09%	48.15%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.98%	1.06%	1.13%	1.12%	1.04%	1.17%	1.27%	1.19%	1.11%	1.07%	1.09%
Common Equity to Total Capital	40.60%	42.58%	43.96%	45.27%	44.19%	47.98%	50.55%	48.02%	48.75%	50.38%	50.73%
Debt to EBITDA	16.47	2.69	2.68	2.68	2.98	2.44	2.29	2.68	2.70	2.64	2.81
Net Debt to EBITDA	12.59	1.98	1.94	2.09	1.95	1.65	1.64	1.70	1.64	1.45	2.18
Long-Term Debt to EBITDA	16.46	2.40	2.39	2.39	2.69	2.03	1.77	2.16	2.17	2.51	2.81
Debt to NOPAT	0.00	5.66	5.49	5.41	5.59	4.29	3.96	4.50	4.56	4.65	4.99
Net Debt to NOPAT	0.00	4.16	3.97	4.23	3.66	2.91	2.84	2.85	2.78	2.55	3.87
Long-Term Debt to NOPAT	0.00	5.06	4.89	4.82	5.05	3.57	3.06	3.62	3.67	4.42	4.99
Altman Z-Score	0.93	1.59	1.77	1.69	1.84	1.71	1.73	1.64	1.66	1.80	1.63
Noncontrolling Interest Sharing Ratio	2.36%	2.44%	2.51%	2.41%	2.31%	2.40%	2.47%	2.41%	2.24%	2.21%	2.26%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.25	1.05	1.06	1.06	1.23	1.04	0.98	1.16	1.18	1.37	1.22
Quick Ratio	0.77	0.67	0.67	0.65	0.81	0.68	0.61	0.75	0.77	0.93	0.71
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14,771	2,619	-13,884	-14,764	393	244	-876	-709	-748	-770	-2,624
Operating Cash Flow to CapEx	812.50%	1,117.02%	288.97%	-185.94%	820.00%	895.10%	164.47%	109.30%	539.09%	783.58%	162.92%
Free Cash Flow to Firm to Interest Expense	-107.03	19.99	-113.80	-112.71	3.03	2.01	-7.96	-6.27	-6.74	-7.26	-27.33
Operating Cash Flow to Interest Expense	4.71	8.02	3.43	-0.91	5.68	7.55	2.27	0.83	5.34	9.91	3.02
Operating Cash Flow Less CapEx to Interest Expense	4.13	7.30	2.25	-1.40	4.98	6.70	0.89	0.07	4.35	8.64	1.17
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.65	1.21	1.23	0.59	0.60	0.60	0.59	0.58	0.59	0.59
Accounts Receivable Turnover	0.00	5.69	0.00	0.00	5.73	5.52	5.73	5.77	5.66	5.48	5.70
Inventory Turnover	0.00	5.65	0.00	0.00	5.40	5.88	5.54	5.42	5.41	5.93	5.66
Fixed Asset Turnover	0.00	8.12	0.00	0.00	7.99	7.79	7.48	7.37	7.30	7.31	7.06
Accounts Payable Turnover	0.00	3.95	0.00	0.00	4.04	3.84	3.78	4.02	4.06	3.94	3.89
Days Sales Outstanding (DSO)	0.00	64.12	0.00	0.00	63.68	66.11	63.75	63.21	64.52	66.55	64.01
Days Inventory Outstanding (DIO)	0.00	64.57	0.00	0.00	67.63	62.05	65.91	67.34	67.43	61.53	64.48
Days Payable Outstanding (DPO)	0.00	92.44	0.00	0.00	90.42	95.00	96.68	90.69	89.81	92.67	93.80
Cash Conversion Cycle (CCC)	0.00	36.25	0.00	0.00	40.88	33.16	32.98	39.86	42.14	35.41	34.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	15,145	14,248	14,293	15,222	15,255	14,713	15,703	16,464	16,474	16,090	18,746
Invested Capital Turnover	0.00	1.28	2.73	2.56	1.29	1.36	1.32	1.26	1.28	1.34	1.22
Increase / (Decrease) in Invested Capital	15,145	-2,148	14,293	15,222	110	465	1,410	1,242	1,219	1,377	3,043
Enterprise Value (EV)	38,840	42,147	48,135	42,775	49,527	41,741	43,134	40,360	40,556	42,927	40,374
Market Capitalization	30,826	35,032	41,252	35,357	42,587	35,473	36,617	33,607	34,074	37,216	32,295
Book Value per Share	$15.67	$15.67	$16.25	$17.09	$18.21	$18.49	$20.09	$21.21	$21.89	$22.79	$23.41
Tangible Book Value per Share	($15.64)	($15.50)	($14.68)	($14.26)	($13.03)	($12.63)	($11.86)	($10.75)	($10.10)	($9.31)	($13.82)
Total Capital	17,563	16,752	16,855	17,234	18,825	17,603	18,177	20,228	20,502	20,602	21,032
Total Debt	10,260	9,442	9,255	9,240	10,313	8,951	8,759	10,275	10,282	10,003	10,134
Total Long-Term Debt	10,253	8,436	8,247	8,233	9,306	7,449	6,757	8,270	8,277	9,495	10,127
Net Debt	7,842	6,938	6,692	7,225	6,745	6,062	6,286	6,512	6,255	5,491	7,849
Capital Expenditures (CapEx)	80	94	145	64	90	102	152	86	110	134	178
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-508	-1,069	-1,041	-520	-593	-1,039	-705	-198	-202	-608	-381
Debt-free Net Working Capital (DFNWC)	1,910	1,435	1,522	1,495	2,975	1,850	1,768	3,565	3,825	3,904	1,904
Net Working Capital (NWC)	1,903	429	514	488	1,968	348	-234	1,560	1,820	3,396	1,897
Net Nonoperating Expense (NNE)	-7.53	55	21	23	13	-28	-54	33	7.22	5.14	8.14
Net Nonoperating Obligations (NNO)	7,842	6,938	6,693	7,228	6,743	6,061	6,285	6,511	6,254	5,491	7,848
Total Depreciation and Amortization (D&A)	153	144	148	149	143	140	136	148	148	146	153
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-5.47%	-5.34%	-2.66%	-3.03%	-5.28%	-3.56%	-0.99%	-1.00%	-2.95%	-1.82%
Debt-free Net Working Capital to Revenue	0.00%	7.34%	7.81%	7.66%	15.21%	9.40%	8.93%	17.85%	18.89%	18.93%	9.08%
Net Working Capital to Revenue	0.00%	2.19%	2.64%	2.50%	10.06%	1.77%	-1.18%	7.81%	8.99%	16.47%	9.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.82	$0.89	$0.82	$0.94	$1.03	$1.58	$1.23	$1.06	$0.98	$1.29	$0.85
Adjusted Weighted Average Basic Shares Outstanding	455M	455M	456M	457M	457M	456M	457M	457M	456M	456M	456M
Adjusted Diluted Earnings per Share	$0.82	$0.89	$0.81	$0.93	$1.02	$1.58	$1.23	$1.06	$0.98	$1.28	$0.85
Adjusted Weighted Average Diluted Shares Outstanding	458M	458M	459M	459M	459M	459M	459M	458M	457M	458M	457M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	455.24M	455.36M	456.47M	456.66M	456.87M	457.30M	457.88M	456.56M	455.52M	455.75M	454.89M
Normalized Net Operating Profit after Tax (NOPAT)	374	471	409	458	503	709	534	533	471	607	419
Normalized NOPAT Margin	7.77%	9.04%	8.80%	9.46%	10.35%	13.32%	11.19%	10.65%	9.16%	10.66%	8.17%
Pre Tax Income Margin	13.19%	11.70%	11.01%	11.94%	13.53%	15.66%	14.49%	12.24%	12.50%	14.39%	9.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	5.61	5.65	5.20	5.42	6.05	7.89	7.29	6.42	6.79	8.74	6.27
NOPAT to Interest Expense	2.71	3.59	3.35	3.49	3.87	5.86	4.86	4.72	4.25	5.73	4.37
EBIT Less CapEx to Interest Expense	5.03	4.93	4.01	4.93	5.36	7.05	5.91	5.66	5.80	7.47	4.42
NOPAT Less CapEx to Interest Expense	2.13	2.88	2.17	3.00	3.18	5.01	3.48	3.96	3.25	4.46	2.51
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	2.54%	3.40%	3.39%	3.12%	2.68%	2.53%	2.55%	2.71%	2.97%	3.24%
Augmented Payout Ratio	0.00%	15.61%	3.40%	3.39%	3.12%	2.68%	2.53%	6.87%	11.45%	12.26%	18.41%

Financials Breakdown Chart

Key Financial Trends

GE HealthCare Technologies (GEHC) shows a pattern of growing revenue, solid cash flow generation, and steady profitability across the latest four years of quarterly data. Here are the most relevant trends for retail investors to consider.

Revenue growth in 2025 quarters: Q4 2025 revenue reached $5.698B, up from Q4 2024’s $5.32B, with a clear sequential rise through 2025 (Q1: $4.778B, Q2: $5.007B, Q3: $5.143B).
Stable gross margins: Gross margin remained in the high-30s to around 40% range in late 2025 (e.g., Q4 2025 gross profit $2.261B on $5.698B revenue, about 39–40%).
Profitability to shareholders improving in Q4 2025: Net income attributable to common shareholders was $588M in Q4 2025, with basic EPS of $1.29 and diluted EPS of $1.28, indicating solid quarterly profitability.
Strong operating cash flow: Cash flow from continuing operating activities was robust in Q4 2025 at $1.05B, with healthier readings across 2025 (Q3: $0.593B; Q2: $0.95B; Q1: $0.25B).
Healthy free cash flow potential: With CFO of about $1.05B in Q4 2025 and capex around $134M, free cash flow for the quarter was roughly $0.92B, signaling meaningful cash generation after capex.
Solid liquidity position: Cash and equivalents around $4.0B+ in 2025 (notably $4.027B in Q3 2025), providing liquidity to fund operations and near-term obligations.
Ongoing R&D and SG&A investment: R&D expenses typically run around $290–344M per quarter and SG&A around $1.0–$1.1B, reflecting continued investment in product development and commercialization.
Modest capex trend: Purchases of property, plant & equipment generally in the $80–134M range per quarter, suggesting steady but controlled capital spend.
Financing outflows weighing on cash: Net cash from financing activities was negative in Q4 2025 (about -$293M), driven by debt repayments and equity-related activity that reduce cash on hand.

05/15/26 03:23 AM ETAI Generated. May Contain Errors.

GE HealthCare Technologies Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GE HealthCare Technologies' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

The last 5 years of GE HealthCare Technologies' net income performance:

2021: $2.29 billion
2022: $1.97 billion
2023: $1.61 billion
2024: $2.05 billion
2025: $2.15 billion

Find out what analysts predict for GE HealthCare Technologies in the coming months.

GE HealthCare Technologies' total operating income in 2025 was $2.76 billion, based on the following breakdown:

Total Gross Profit: $8.25 billion
Total Operating Expenses: $5.49 billion

Over the last 4 years, GE HealthCare Technologies' total revenue changed from $17.59 billion in 2021 to $20.63 billion in 2025, a change of 17.3%.

GE HealthCare Technologies' total liabilities were at $26.31 billion at the end of 2025, a 7.7% increase from 2024, and a 46.6% increase since 2022.

In the past 3 years, GE HealthCare Technologies' cash and equivalents has ranged from $1.45 billion in 2022 to $4.51 billion in 2025, and is currently $4.51 billion as of their latest financial filing in 2025.

Over the last 4 years, GE HealthCare Technologies' book value per share changed from 0.00 in 2021 to 22.79 in 2025, a change of 2,278.7%.

Related Companies

Financial statements for NASDAQ:GEHC last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GE HealthCare Technologies (GEHC) Financials

Financials Breakdown Chart

Key Financial Trends

GE HealthCare Technologies Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GE HealthCare Technologies (GEHC) Financials

Annual Income Statements for GE HealthCare Technologies

Quarterly Income Statements for GE HealthCare Technologies

Annual Cash Flow Statements for GE HealthCare Technologies

Quarterly Cash Flow Statements for GE HealthCare Technologies

Annual Balance Sheets for GE HealthCare Technologies

Quarterly Balance Sheets for GE HealthCare Technologies

Annual Metrics And Ratios for GE HealthCare Technologies

Quarterly Metrics And Ratios for GE HealthCare Technologies

Financials Breakdown Chart

Key Financial Trends

GE HealthCare Technologies Financials - Frequently Asked Questions

When does GE HealthCare Technologies' financial year end?

How has GE HealthCare Technologies' net income changed over the last 4 years?

What is GE HealthCare Technologies' operating income?

How has GE HealthCare Technologies' revenue changed over the last 4 years?

How much debt does GE HealthCare Technologies have?

How much cash does GE HealthCare Technologies have?

How has GE HealthCare Technologies' book value per share changed over the last 4 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools